Karyopharm Therapeutics Stock Drops 12.71% Amid $30 Million Financing Announcement

martes, 24 de marzo de 2026, 10:11 am ET1 min de lectura
KPTI--

Karyopharm Therapeutics (KPTI) shares declined 12.71% to $6.66 after a $30M financing announcement. The deal includes warrants that amplify shareholder dilution worries. Capital will support selinexor development and advanced oncology trials. Upcoming Phase 3 data is expected to be a critical stock price driver.

Karyopharm Therapeutics Stock Drops 12.71% Amid $30 Million Financing Announcement

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios